• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

437个具有催化活性的人类蛋白激酶结构域活性形式的AlphaFold2模型。

AlphaFold2 models of the active form of all 437 catalytically competent human protein kinase domains.

作者信息

Faezov Bulat, Dunbrack Roland L

机构信息

Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia PA 19111, USA.

Kazan Federal University, Kazan, Russian Federation.

出版信息

bioRxiv. 2023 Sep 3:2023.07.21.550125. doi: 10.1101/2023.07.21.550125.

DOI:10.1101/2023.07.21.550125
PMID:37547017
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10401967/
Abstract

Humans have 437 catalytically competent protein kinase domains with the typical kinase fold, similar to the structure of Protein Kinase A (PKA). Only 155 of these kinases are in the Protein Data Bank in their active form. The active form of a kinase must satisfy requirements for binding ATP, magnesium, and substrate. From structural bioinformatics analysis of 40 unique substrate-bound kinases, we derived several criteria for the active form of protein kinases. We include requirements on the DFG motif of the activation loop but also on the positions of the N-terminal and C-terminal segments of the activation loop that must be placed appropriately to bind substrate. Because the active form of catalytic kinases is needed for understanding substrate specificity and the effects of mutations on catalytic activity in cancer and other diseases, we used AlphaFold2 to produce models of all 437 human protein kinases in the active form. This was accomplished with templates in the active form from the PDB and shallow multiple sequence alignments of orthologs and close homologs of the query protein. We selected models for each kinase based on the pLDDT scores of the activation loop residues, demonstrating that the highest scoring models have the lowest or close to the lowest RMSD to 22 non-redundant substrate-bound structures in the PDB. A larger benchmark of all 130 active kinase structures with complete activation loops in the PDB shows that 80% of the highest-scoring AlphaFold2 models have RMSD < 1.0 Å and 90% have RMSD < 2.0 Å over the activation loop backbone atoms. Models for all 437 catalytic kinases are available at http://dunbrack.fccc.edu/kincore/activemodels. We believe they may be useful for interpreting mutations leading to constitutive catalytic activity in cancer as well as for templates for modeling substrate and inhibitor binding for molecules which bind to the active state.

摘要

人类拥有437个具有典型激酶折叠的催化活性蛋白激酶结构域,其结构与蛋白激酶A(PKA)相似。其中只有155种激酶以活性形式存在于蛋白质数据库中。激酶的活性形式必须满足结合ATP、镁和底物的要求。通过对40种独特的底物结合激酶进行结构生物信息学分析,我们得出了蛋白质激酶活性形式的几个标准。我们不仅包括对激活环DFG基序的要求,还包括对激活环N端和C端片段位置的要求,这些片段必须适当放置以结合底物。由于理解癌症和其他疾病中底物特异性以及突变对催化活性的影响需要催化激酶的活性形式,我们使用AlphaFold2生成了所有437种人类蛋白激酶的活性形式模型。这是通过使用来自蛋白质数据库(PDB)的活性形式模板以及查询蛋白的直系同源物和近同源物的浅层多序列比对来完成的。我们根据激活环残基的pLDDT分数为每种激酶选择模型,表明得分最高的模型与蛋白质数据库中22个非冗余底物结合结构的RMSD最低或接近最低。对蛋白质数据库中所有130个具有完整激活环的活性激酶结构进行的更大规模基准测试表明,得分最高的AlphaFold2模型中80%在激活环主链原子上的RMSD < 1.0 Å,90%的RMSD < 2.0 Å。所有437种催化激酶的模型可在http://dunbrack.fccc.edu/kincore/activemodels获取。我们认为它们可能有助于解释导致癌症中组成型催化活性的突变,以及作为模拟与活性状态结合的分子的底物和抑制剂结合的模板。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/b6fad79a09f7/nihpp-2023.07.21.550125v2-f0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/1216e54f9931/nihpp-2023.07.21.550125v2-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/569ab491a1d6/nihpp-2023.07.21.550125v2-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/a2a55ebfe1a6/nihpp-2023.07.21.550125v2-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/9a2490c64901/nihpp-2023.07.21.550125v2-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/6713347ddcca/nihpp-2023.07.21.550125v2-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/d98f85257c3c/nihpp-2023.07.21.550125v2-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/73acf750dcc7/nihpp-2023.07.21.550125v2-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/d7a957960370/nihpp-2023.07.21.550125v2-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/3ea3d968bb0b/nihpp-2023.07.21.550125v2-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/a89695bca17f/nihpp-2023.07.21.550125v2-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/1f2280caba4b/nihpp-2023.07.21.550125v2-f0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/9461149cff77/nihpp-2023.07.21.550125v2-f0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/b6fad79a09f7/nihpp-2023.07.21.550125v2-f0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/1216e54f9931/nihpp-2023.07.21.550125v2-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/569ab491a1d6/nihpp-2023.07.21.550125v2-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/a2a55ebfe1a6/nihpp-2023.07.21.550125v2-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/9a2490c64901/nihpp-2023.07.21.550125v2-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/6713347ddcca/nihpp-2023.07.21.550125v2-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/d98f85257c3c/nihpp-2023.07.21.550125v2-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/73acf750dcc7/nihpp-2023.07.21.550125v2-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/d7a957960370/nihpp-2023.07.21.550125v2-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/3ea3d968bb0b/nihpp-2023.07.21.550125v2-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/a89695bca17f/nihpp-2023.07.21.550125v2-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/1f2280caba4b/nihpp-2023.07.21.550125v2-f0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/9461149cff77/nihpp-2023.07.21.550125v2-f0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91a/10486845/b6fad79a09f7/nihpp-2023.07.21.550125v2-f0013.jpg

相似文献

1
AlphaFold2 models of the active form of all 437 catalytically competent human protein kinase domains.437个具有催化活性的人类蛋白激酶结构域活性形式的AlphaFold2模型。
bioRxiv. 2023 Sep 3:2023.07.21.550125. doi: 10.1101/2023.07.21.550125.
2
Kincore: a web resource for structural classification of protein kinases and their inhibitors.Kincore:一个用于蛋白质激酶及其抑制剂的结构分类的网络资源。
Nucleic Acids Res. 2022 Jan 7;50(D1):D654-D664. doi: 10.1093/nar/gkab920.
3
A historical overview of protein kinases and their targeted small molecule inhibitors.蛋白激酶及其靶向小分子抑制剂的历史概述。
Pharmacol Res. 2015 Oct;100:1-23. doi: 10.1016/j.phrs.2015.07.010. Epub 2015 Jul 21.
4
Exploring the Druggable Conformational Space of Protein Kinases Using AI-Generated Structures.利用人工智能生成的结构探索蛋白激酶的可成药构象空间。
bioRxiv. 2023 Sep 2:2023.08.31.555779. doi: 10.1101/2023.08.31.555779.
5
Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.已获 FDA 批准的小分子磷脂酰肌醇 3-激酶抑制剂的特性,这些抑制剂用于治疗恶性肿瘤。
Pharmacol Res. 2021 Jun;168:105579. doi: 10.1016/j.phrs.2021.105579. Epub 2021 Mar 26.
6
Two structures of the catalytic domain of phosphorylase kinase: an active protein kinase complexed with substrate analogue and product.磷酸化酶激酶催化结构域的两种结构:一种与底物类似物和产物复合的活性蛋白激酶。
Structure. 1995 May 15;3(5):467-82. doi: 10.1016/s0969-2126(01)00180-0.
7
Classifying protein kinase conformations with machine learning.利用机器学习对蛋白激酶构象进行分类。
Protein Sci. 2024 Apr;33(4):e4918. doi: 10.1002/pro.4918.
8
Defining a new nomenclature for the structures of active and inactive kinases.定义活性和非活性激酶结构的新命名法。
Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):6818-6827. doi: 10.1073/pnas.1814279116. Epub 2019 Mar 13.
9
Mutation of recombinant catalytic subunit alpha of the protein kinase CK2 that affects catalytic efficiency and specificity.蛋白激酶CK2重组催化亚基α的突变,其影响催化效率和特异性。
Protein Eng. 2000 Apr;13(4):291-8. doi: 10.1093/protein/13.4.291.
10
The structure of dimeric ROCK I reveals the mechanism for ligand selectivity.二聚体ROCK I的结构揭示了配体选择性的机制。
J Biol Chem. 2006 Jan 6;281(1):260-8. doi: 10.1074/jbc.M508847200. Epub 2005 Oct 24.

引用本文的文献

1
A comprehensive exploration of the druggable conformational space of protein kinases using AI-predicted structures.利用人工智能预测结构全面探索蛋白激酶的可成药性构象空间。
PLoS Comput Biol. 2024 Jul 24;20(7):e1012302. doi: 10.1371/journal.pcbi.1012302. eCollection 2024 Jul.